November 26, 2018
Daiichi Sankyo said on November 22 that the US FDA has given priority review status to its FLT3 inhibitor quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), with an action date set for May...read more